Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc.

The latest announcement is out from Concordia Financial Group ( ($JP:7186) ). Yokohama Financial Group has disclosed progress on its ongoing share ...

Yokohama Financial Group Reports Progress on ¥20 Billion Share Buyback Program

An update from Sumer Varlik Yonetim A.S. ( ($TR:SMRVA) ) is now available. The Central Dematerialised System has announced a series of scheduled re...

Turkish CDS Announces Coordinated Debt Redemptions and Coupon Payments for August 2026

The latest update is out from Creditwest Faktoring A.S. ( ($TR:CRDFA) ). A series of new debt securities and lease certificates, including bills fr...

Turkish issuers launch new TL debt instruments for qualified investors

An announcement from Creditwest Faktoring A.S. ( ($TR:CRDFA) ) is now available. Creditwest Faktoring A.S. has completed the issuance and full rede...

Creditwest Faktoring Completes Redemption of TLREF-Linked TRY 60 Million Bill

Creditwest Faktoring A.S. ( ($TR:CRDFA) ) has issued an update. Creditwest Faktoring A.Ş. has completed the domestic sale to qualified investors of...

Creditwest Faktoring Raises TRY 71 Million via Floating-Rate Bill

The latest announcement is out from Creditwest Faktoring A.S. ( ($TR:CRDFA) ). Creditwest Faktoring A.S. has issued a TRY 60 million floating-rate ...

Creditwest Faktoring Raises TRY 60 Million with Rated Floating-Rate Bill

The latest announcement is out from Creditwest Faktoring A.S. ( ($TR:CRDFA) ). Creditwest Faktoring A.S. has called an extraordinary general assemb...

Creditwest Faktoring Calls Extraordinary Meeting to Reshape Board

The latest announcement is out from Creditwest Faktoring A.S. ( ($TR:CRDFA) ). Creditwest Faktoring A.S. has approved the candidacies of Mehmet Şer...

Creditwest Faktoring Moves to Strengthen Board With New Independent Members

Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QMCO) ), ( ($ONON) ), ( ($CRDF) ) and ( ($ADSK) ). Here is a breakdown of their recent


	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDF	$1.09	+0.93%	437.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDF	$1.09	+0.9%	437.33K
3
4
5
6

CRDF

Get Cardiff Oncology, Inc. Data in Excel

Get Cardiff Oncology, Inc. Data in Excel